Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW501516 in Dyslipidemia
NCT00158899Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of GW501516 in dyslipidemia (5 arms), sponsored by GSK. Primary endpoint: Change from baseline in fasting plasma HDLc concentration at 12 weeks. Started Aug 2004; status: completed.
02
Drugs
GW501516
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00158899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158899.